Local businesses have seen needed venture capital and loans in greater abundance in recent months.
The amount of venture capital investment funneled to Montgomery County and Washington-area companies in 2013’s first quarter jumped by 30 percent from the same period a year ago, according to a recent report.
The $286.3 million invested in local companies in the first three months was the most in the quarter in five years, according to the report from PricewaterhouseCoopers LLP and the National Venture Capital Association, based on data by Thomson Reuters.
It’s true that, geographically speaking, Maryland is a small state. But as the old saying goes, “Good things come in small packages,” and that is especially true when it comes to the resources, advice and technical expertise that Maryland offers inventors and technology entrepreneurs.
From university laboratories and research centers (such as The Johns Hopkins Applied Physics Laboratory, University of Maryland’s Office of Technology Commercialization or University of Maryland – Baltimore City’s ACTiVATE) to state organizations (Maryland Biotechnology Center or the Department of Business and Economic Development), a wide variety of entities are working to help entrepreneurs develop and market their inventions.
Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.
The University of Maryland School of Medicine is launching a $500 million fundraising campaign, the largest in the school’s history.
The school plans to officially launch the capital campaign, “Transforming Medicine Beyond Imagination,” at its annual gala May 11. The event is considered a critical fundraiser for the school’s research and clinical programs.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license agreement with United Therapeutics Corporation (Nasdaq:UTHR) for the use of Pluristem’s PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH).
Under the terms of the agreement, United Therapeutics will receive exclusive worldwide licensing rights for the development and commercialization of the future product for treating PH patients. Pluristem will retain all manufacturing rights; participate in the pre-clinical and clinical trial activities, as well as provide the commercial grade product.
A Johns Hopkins University faculty member will be helping advise the National Institutes of Health about research topics with the most promise for addressing public health challenges.
Janice E. Clements, vice dean for faculty at the Johns Hopkins University School of Medicine, has been selected to serve on the Council of Councils for NIH. Clements was among 10 individuals newly selected to serve on the 27-member council. Her term ends in October 2015.
UK pharmaceuticals giant GlaxoSmithKline has unveiled an “open innovation” platform through which it will publish data from its clinical trials online so it can be analysed by external researchers.
The online system allows scientists to submit a to request access anonymised drug trial data. Each request will be judged a panel of external experts appointed by GSK, and applicants must agree to publish their own findings.
Join NFTE Baltimore as an honored guest at out Regional City Wide Business Plan Competition. The top size finalists will present and defend their business plans before a prestigious panel of judges and an audience of top buiness and school leaders. The networking reception will include a Student Showcase and we will also honor NFTE’s biggest supporters of youth entrepreneurship.
University of Baltimore William T. Thumel Sr. Business Center 11 West Mount Royal Avenue
May 15, 2013 8:00am – 10:00am Tower Club, Tysons Corner
Attracting and retaining key employees is a challenge every business faces, and government contractors know that a valuable contract can hinge on making the right staffing choices. Savvy government contractors also recognize the necessity to maximize human capital within the constraints of sequestration, continuing resolution and lowest price technically acceptable contracts.
You’re invited to this breakfast workshop to learn about powerful employee incentive compensation strategies that can provide significant competitive advantages for your business. These often underutilized plans can attract top quality employees through cash, equity and other equity-linked compensation methods. In addition to creating great work environments, innovative incentive plans allow government contractors to be successful amidst the current era of regulatory challenges.
Venture capital firm Grotech Ventures has raised $225 million that it plans to invest in early-stage technology companies.
The $225 million round, called Grotech Ventures II, is the firm’s eight fund. The firm had originally planned to raise $220 million but expanded to include new investors, said Grotech Managing General Partner and Founder Frank Adams.
Governor Martin O’Malley today officially launched data.maryland.gov – Maryland’s first statewide open data portal that will provide researchers, entrepreneurs, public servants and citizens with a wide variety of data to support transparency and innovation in government. Data such as vendor payments, vehicle accidents, licensed veterinary clinics, GIS mapping data, and per capita electricity consumption will all be made available and housed in a central place for the public.
The Governor made this announcement at a panel discussion hosted in conjunction with the Future of Information Alliance (FIA) – a transdisciplinary partnership between the University of Maryland, College Park and 10 founding partners. The panel featured “futurists” and over 120 students, entrepreneurs and public servants who spoke about the importance of big data to better serve and inform the public.
As the provisions of the Affordable Care Act and HITECH Act are rolled out, providers and payers are looking for ways to address pain points varying from improving patient engagement and remote monitoring to helping consumers better understand their insurance options to making better use of patient information in the context of big data.
Some accelerators are helping members of the healthcare ecosystem and entrepreneurs find each other. These four healthcare accelerators are currently looking for applicants.
Version 2.0 of a plan to create an Office of mHealth in the U.S. Food and Drug Administration should be out soon. The office of U.S. Rep. Mike Honda, Silicon Valley’s Democratic Congressman who authored the legislation, said the next draft will at the least fine-tune the way the office would work with other federal agencies.
But is the big-ticket item – a new office dedicated to adding more context and understanding of mHealth within the federal agency – the most interesting thing about the bill? I don’t think so. Read through the details and see if you agree.
The University City Science Center is collaborating with the Canadian Consulate General to pilot a business accelerator for health information and communication technology companies from Canada.
Opening on May 13, 2013, the Canadian Technology Accelerator at the Science Center will provide a 3-6 month “market immersion” experience for Canadian health IT companies, leveraging the Science Center’s resources and networks through its Port business incubator.
If you’re a startup working on a product for the healthcare industry, Boston is the place to be. During a trip to Bean Town, I was curious to hear what startup founders found most challenging in a city so rich with resources. The usual gripes I usually hear elsewhere, like troubles with seed funding or FDA regulation, didn’t come up as much. Instead, these founders seemed to find the more personal elements of entrepreneurship most challenging. Many times, I found myself talking to people who had made a shift from working in tech or research to becoming a business owner.
The community realizes that, though. In addition to numerous startup accelerators and incubators, Boston is home to lots of collaborative startup space.
Venture capitalists are pushing to allow more highly educated immigrants into the U.S., saying this is essential to ensuring that the country remains an innovation leader.
One argument they use is that immigrants create jobs by starting companies. Scott Sandell, general partner at New Enterprise Associates who leads the venture firm’s technology investing, wants to support this assertion with better data.
I had the privilege to meet with and speak to the local Healthcare meet-up recently (thanks to Pete Kanee at www.healthcare.mn) and as part of my discussion, I shared a list of things that I’d encourage the local (healthcare) startups to continue to keep in mind as they grow their companies.
These are relevant to not only healthcare-focused startups but all startups for that matter. They’re pretty common, but in my recent conversations with healthcare entrepreneurs, I found many of these needing to be brought up as part of the dialogue.
Health and Human Services Secretary Kathleen Sebelius is asking companies for financial donations to help implement President Barack Obama’s healthcare overhaul, months before it is due to take effect.
In telephone calls that began around March 23, officials say, Obama’s top healthcare adviser has been seeking assistance from companies in the healthcare field and other industries as well as from healthcare providers, patient advocacy groups, churches and other charitable organizations.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Ingenuity Systems, a 15-year veteran of the biological software business, showed today that you can make money not just by generating DNA data, but by helping scientists figure out what it means.
Redwood City, CA-based Ingenuity said today it has agreed to be acquired by Netherlands-based Qiagen for $105 million in cash. Ingenuity, a private company, was able to fetch that price after it closed last year with about $20 million in net sales, the companies said in a statement. The deal is expected to start adding to Qiagen’s profits in 2015, the companies said.
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
Panelists include:
Lauren Abrey Global Development Team Lead, Genetech/Roche
Neil Exter Partner, Third Rock
Brian Gallagher Partner, SROne
Michael Glutch Managing Director, Medimmune Ventures
Perry Nisen Senior VP of Science Transactions, Pfizer
Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
The Maryland Technology Enterprise Institute (Mtech) today announces the winners of the inaugural University of Maryland Business Model Challenge.
The two winning UMD entrepreneur teams were selected from among 44 initial entries and 11 finalist teams, six of whom were selected to present the results they achieved through the Challenge’s multi-week lean startup workshop to an expert panel of judges on April 26 at the University of Maryland.
Late last week, leaders from across the global vaccine industry gathered at the 6th Annual Vaccine Industry Excellence (ViE) awards ceremony during the World Vaccine Congress in Washington, D.C, to honor the industry’s best and brightest. Immunovaccine is proud to announce that chief executive officer John Trizzino was awarded this year’s Best Biotech CEO prize during the ceremony.
In considering candidates for the Best Biotech CEO award, judges evaluated a number of important criteria including:
Degree of outstanding commitment to disease prevention and treatment
Level of exemplary leadership throughout the year
Contribution to company performance, communication and vision
Influence within the industry
Achievements made with regards to company positioning and status
The Ernst & Young Entrepreneur Of The Year 2013 finalists have a lot to celebrate. They’ve built their dream companies. Expanded. Innovated. And now Ernst & Young is recognizing them for their achievements. Help us congratulate these outstanding entrepreneurs. Join us at this years event and see who will take home top honors.
Johns Hopkins says it is working on its largest-ever fundraising campaign, which aims to raise $4.5 billion by the end of 2017.
The university and health system announced the effort Saturday. The idea is to create as many as 300 endowed professorships and generate nearly $700 million for undergraduate financial aid and graduate student fellowships.
Leveraging USDA-ARS Partnerships and Capabilities to Help Your Business
PRESENTERS:
Robert Griesbach, Ph.D. Deputy Assistant Administrator Office of Technology
James Poulos, III Technology Transfer Coordinator
Cathy Cohn Technology Transfer Liaison
Abstract:
Agricultural Research Services (ARS) is the research arm of the Department of Agriculture that develops and transfers solutions to agricultural problems affecting Americans every day, from field to table. To accelerate the development of new products and help move technologies into the marketplace, ARS often partners with companies and research institutions early on in the research process. Working collaboratively alongside ARS, partners are able access and implement ARS technologies, resources and expertise to further develop specific products and create new ones. ARS conducts research in 800 projects at 90 locations including six pilot plants and six human nutrition centers. With a long standing commitment to technology transfer, ARS works closely with the private sector to ensure research outcomes are adopted. Please join us to learn about the wide range of expertise and capabilities from ARS that can be used to grow your business
Emergent BioSolutions Inc. (NYSE:EBS) announced its participation in the Defence against Terrorism Programme of Work (DAT POW) workshop conducted by the North Atlantic Treaty Organization (NATO) Emerging Security Challenges Division at the Counter Terror Expo in London. An initial session of the workshop was focused on the future capabilities and protection of the Special Operations Forces (SOF) community on areas such as Improvised Explosive Devices (IEDs), Intelligence, Surveillance, Reconnaissance (ISR), Biometrics and Forensics, Information Sharing Systems, Tactical Computer, Communications, Command and Control (C4), and Force Protection.
“Emergent strongly supports NATO’s initiatives to educate on protecting those who protect the population,” said Allen Shofe, Executive Vice President of Corporate Affairs, Emergent BioSolutions. “NATO DAT POW workshops are highly relevant and informative as they cover various activities undertaken and coordinated by NATO countries.”
The University of Maryland Institute for Bioscience and Biotechnology Research (IBBR) invites you to participate in the 5th Biennial NMR Day symposium on Friday, May 17, 2013, at our facility in Rockville, Maryland.
IBBR (formerly CARB) hosts a biennial meeting, designed to promote discussion and collaboration among scientists active in the application of biomolecular NMR to modern problems in structural biology and biotechnology. The symposium speakers are internationally recognized in the application of NMR to biological systems
The National Capitol Area Local Chapter of SoPE in concert with JHU Carey Business School, MedChi, Zanvyl Krieger School of Arts and Sciences Center for Biotechnology Education, Montgomery County Medical Society, and the Medical Society of Northern Virginia presents:
“Working with Industry in the Life Sciences – What does it Really Take?”
Tuesday, May 14th, 2013–6:00PM to 8:00PM
Johns Hopkins University, Montgomery County Campus, Building III – 9605 Medical Center Drive, Room 121
Join us as we bring together top leaders and innovators in the fields of Cybersecurity, Health IT, and Mobile Technology. Learn where the technology is leading these 3 sectors and the opportunities that exist for real estate brokers and developers who want to capitalize on these expanding industries.
Hear from leaders including Dr. Freeman Hrabowski, one of Time Magazine’s “World’s 100 Most Influential People”, as well as Dr. Mark Doms, Under Secretary for Economic Affairs with the United States Department of Commerce, who serves as a top economic advisor to the Obama Administration and to the Department of Commerce.
Startup Maryland today announced dates (September 9 – 27) and the rough route for the Pitch Across Maryland 2.0, the second annual state-wide tour and celebration of entrepreneurship and startup companies.
Referred to by CBS News affiliate WBOC-TV 16 as “Opportunity on Wheels,” the inaugural Pitch Across Maryland tour was an overwhelming success last year. The bus traversed the state all in the name of celebrating entrepreneurship. A sampling of details, key data and results from last year’s tour follow:
The Johns Hopkins Bloomberg School of Public Health has partnered with Barclays Bank to develop a youth entrepreneurship program with the Bloomberg School’s Center for American Indian Health. The new initiative is aimed at designing an evidence-based program to inspire American Indian youth to stay in school and create business and social entrepreneurship opportunities.
As part of the partnership, Barclays will provide a total of $1.2 million in program funding over the course of the next three years. Additionally, Barclays employees will lend their business expertise and serve as mentors to program participants. Program efforts will first concentrate on the White Mountain Apache Reservation in Arizona with the ultimate goal to implement youth entrepreneurship programs in poverty stricken communities throughout the world.
Earlier this month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of 2013. The report, which is prepared by NVCA and PriceWaterhouseCoopers LLP using data from Thomson Reuters, indicates that venture capitalists invested $5.9 billion in 863 deals in the first quarter, which constituted a 12% decrease in dollars and a 15% decrease in deals as compared with the fourth quarter of 2012, when $6.7 billion was invested in 1,013 deals (see chart below; data from MoneyTree Reports).
Somewhere between venture funding and bank loans is a kind of investment that seems to fly under the radar, but apparently over the last several years has become increasingly popular for biotech companies beyond the startup stage looking for growth capital.
Royalty financing is the vehicle that Capital Royalty L.P. will use to invest its new $805 million fund in healthcare products and technologies. But (sorry startups), it’s not looking for early-stage companies. Capital Royalty says it invests in companies with FDA-approved healthcare products that are generating revenue. These are companies looking to make acquisitions, expand into new markets or develop new products with investments of $20 million to $200 million.
Chandra Duggirala, maker of an experimental device for type two diabetes, is on the verge of giving up.
Duggirala’s company, Novobionics, raised a small amount of funding for a noninvasive technology that mimics the effects of gastric bypass surgery. The device tricks the gastro-intestinal tract into thinking it is full, which slows the rate of nutrient absorption, thereby easing suffering for diabetes patients.
President Barack Obama dropped in on the National Academy of Sciences today to help it celebrate its 150th birthday.
The president said he’s committed to increased public investment in scientific research, contending this is necessary in order for the U.S. to retain its technological edge. Under sequestration, however, federal spending on research is being cut, not increased.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, today announced its selection of Ken Malone, Ph.D., of Early Charm Ventures, as the first BHI Entrepreneur-in-Residence (EIR) assigned to work directly with UM Ventures. Dr. Malone, a serial entrepreneur who has founded or been an officer of five biotechnology or advanced materials companies, will help advance the commercialization efforts of new start-up companies based upon innovative discoveries coming out of research programs at the University of Maryland (UMD) College Park and Baltimore.
“We’re thrilled to name Ken Malone as an EIR,” said Richard Bendis, BHI President & CEO. “Ken and I have a long history of working together, so I know first hand that he has the experience, drive and perspective to be a true asset to BHI and to the many start-ups he’ll serve from University of Maryland in support of the newly launched UM Ventures initiative.” Dr. Malone will assist any interested UM start-ups once they have been launched.
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
Panelists include:
Lauren Abrey Global Development Team Lead, Genetech/Roche
Neil Exter Partner, Third Rock
Brian Gallagher Partner, SROne
Michael Glutch Managing Director, Medimmune Ventures
Perry Nisen Senior VP of Science Transactions, Pfizer
Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
Time-reversal techniques for optimizing broadband communication networks and rapid prototyping of microfluidics devices were among the Clark School of Engineering inventions recognized as the most promising new technologies at the University of Maryland Invention of the Year Awards.
The University of Maryland’s Office of Technology Commercialization (OTC) hosted the 26th Annual Invention of the Year Awards reception on Tuesday, April 16, 2013 from 4:30-6:00 pm at the University of Maryland Golf Course Club House.
The Biotechnology Industry Organization (BIO) is pleased to announce the election of Rachel King, President and CEO, GlycoMimetics, Inc, as the new Chair of its Board of Directors for the 2013-2014 term, and the election of David Pyott, Chairman, President, & CEO, Allergan, Inc., as its new Board Secretary. BIO also is pleased to announce the re-election of Mark Skaletsky, Chairman & CEO, Fenway Pharmaceuticals, Inc., as Board Treasurer, and the election of 19 Directors to serve on BIO’s Board Executive Committee for the new term. In addition, BIO welcomes the election of eight new members to its Board of Directors, voted upon at this year’s 2013 BIO International Convention.
“Rachel King brings a depth of industry experience and passion for advocacy that will serve BIO and its members well,” said Jim Greenwood, BIO President & CEO. “I look forward to working closely with Rachel and our newly-constituted Board of Directors in the years to come.”
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an asset purchase agreement to acquire the Healthcare Protective Products Division (HPPD) of Bracco Diagnostics Inc. in an all-cash transaction that includes payment of $26.0 million upon closing. The acquisition will diversify and expand Emergent’s biodefense franchise by adding product sales from HPPD’s marketed chemical countermeasure, RSDL (Reactive Skin Decontamination Lotion). The acquisition offers Emergent an opportunity to leverage its core capabilities in manufacturing, government contracting, government sales, and product distribution as it looks to substantially expand sales of RSDL in the attractive and growing chemical countermeasure market.
“This acquisition directly supports our ongoing growth plan, which includes acquiring revenue generating, profitable products and businesses that address the needs of U.S. and allied foreign governments across the CBRN spectrum,” stated Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. “Our relationships, combined with those of HPPD, with the U.S. Government and foreign ministries of defense, as well as worldwide distributor relationships addressing first responder markets, should enable us to grow revenues from RSDL and to expand and enhance Emergent’s leadership position as a premier supplier of CBRN countermeasures.”
Last year AstraZeneca’s ($AZN) MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. This year, MedImmune R&D chief Bahija Jallal tells me, there will be no letup in talent scouting. “If we do as little or more than last year,” says Jallal, “I would be happy.”
Echoing late-stage R&D chief Briggs Morrison–who spoke with me at BIO last week–Jallal singled out cardiovascular/metabolics, respiratory and cancer as key fields for new deals. She noted particular interest in brown fat, a focus for weight-loss fans, and immunotherapeutics, which has emerged as one of the hottest sectors in oncology R&D.
ETC, Baltimore City’s technology innovation center, announced today that it has chosen a new Baltimore City location to house it’s award winning technology incubator when its current Canton lease expires in October 2013. The ETC will move to 101 N. Haven Street, an adaptive reuse of an historic industrial building that was once home to the King Cork and Seal Company. The recently renovated building is located near Highlandtown with easy access to I-95 and is within the Enterprise Zone and a HUBZone. The ETC will maintain space in its other location at Johns Hopkins University – Eastern Campus on 33rd Street.
“The Emerging Technology Center has championed small business development and job creation in Baltimore for years, and we are proud to have supported their efforts,” said Baltimore Mayor Stephanie Rawlings-Blake. “We wish them the best of luck and success in their new location. I’m confident that the ETC will continue to be an important driver of innovation and entrepreneurship in the city. ”
Maryland often has been at the forefront of innovation with a longstanding reputation for investing in science and technology to capture new opportunities for economic growth. This year’s legislative session was no different. Lawmakers backed Gov. Martin O’Malley’s proposals to support the state’s bioscience sector, expand the R&D tax credit, enhance workforce training, and promote measures to establish the state as a leader in cybersecurity.
I wanted to share some data with you that illustrates the strength of Montgomery County’s business community: total employment in the County grew by nearly 25,000 jobs – from 631,000 jobs in 2010 to 655,800 jobs in 2012! This is impressive given the economic climate and shows the resiliency and fortitude of our local businesses – large and small.
The top job gaining sector was professional, scientific and technical services, which added almost 5,300 jobs beteen 2010 and 2012. The other top growing sectors were government, retail trade and health care and social assistance, each adding over 3,000 jobs during the three year period.
MedImmune has acquired Ann Arbor-based AlphaCore Pharma, creating another exit for a local up-and-coming start-up.
MedImmune, the global biologics research and development arm of AstraZeneca, has not disclosed the acquisition price nor its intentions on whether to keep the start-up in Tree Town. Tracy Rossin, director of corporate public relations for MedImmune, did write in an email that the company does “not have plans to expand its operations/workforce in Ann Arbor.” She does add that her firm is “planning to incorporate AlphaCore Pharma into the larger AstraZeneca organization.”
What if you could create a biotech startup focused on treating a rare disease, with a drug candidate already in hand, and high odds of success in clinical trials?
That’s the concept that crystallized in former MedImmune executive David Mott’s mind through decades of experience in the life sciences sector. The idea ultimately led him to start a Cambridge, MA-based biotech incubator called Cydan. This new organization, formally announced this month, has been staffed with a hand-picked squad of specialists tasked with churning out a lineup of small companies that make drugs for orphan diseases.
The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR Phase II projects to the commercialization stage by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. The Bridge Award encourages business relationships between applicant small business concerns and third-party investors/strategic partners who can provide substantial financing to help accelerate the commercialization of promising new products and technologies that were initiated with SBIR funding. In particular, applicants are expected to leverage their previous SBIR support, as well as the opportunity to compete for additional funding through the NHLBI Bridge Award program, to attract and negotiate third-party financing needed to advance a product or technology toward commercialization. The applicant’s ability to secure independent third-party investor funds that equal or exceed the total amount of the NHLBI funds being requested over the entire Bridge Award project period will help to validate the commercial potential that is essential for the SBIR projects solicited under the Bridge Award program. It is anticipated that many of the partnerships between small businesses and third-party investors will involve a considerable level of project due diligence by the private sector, thereby increasing the likelihood of commercial success for the funded projects. In light of these goals, the NHLBI strongly encourages applicants to establish business relationships with investors, strategic partners or both that have appropriate prior experience in commercializing emerging biomedical technologies.
Holding the keys to the future of health care and medicine is not something many children dream of doing.
But Bahija Jallal, executive vice president of AstraZeneca’s (AZN) biologics arm, MedImmune, knew from a very young age that was the career she was destined for.
The University of Maryland has signed an agreement for a student-exchange program with the University of Jordan that will boost research and the flow of students between College Park and the Middle East country’s largest and oldest university.
The announcement of the pact by University of Maryland President Wallace D. Loh comes as a delegation led by Gov. Martin O’Malley visits Jordan on the first leg of an eight-day trip to Jordan and Israel.
A doctor might ask for a patient’s family disease history, or exercise or smoking habits, but whether they have trouble getting food onto the table or paying energy bills is unlikely to appear on any clinic questionnaire.
Those sorts of factors could have just as much, if not more, of an impact on a person’s everyday health, argue the founders of a startup out of the Johns Hopkins University. Their company, Healthify, is giving clinics that serve largely low-income populations the means to gather and use that information.
The Biotechnology Industry Organization (BIO) today issued the annual Scientific American Worldview Report and Bio-Innovation Scorecard. On Wednesday, April 24, the Scientific American Worldview Super Session will take place during the 2013 BIO International Convention, the global biotechnology event, in Chicago, Ill. at McCormick Place.
Moderated by Fareed Zakaria, author, journalist and host of CNN’s Fareed Zakaria GPS, the Convention Super Session is the marquee discussion forum among industry leaders on the state of biotech hubs and innovation around the globe. Panelists include Trevor Mundel, President, Global Health Program for The Bill & Melinda Gates Foundation; Robert Hariri, Chief Executive Officer, Celgene Cellular Therapeutics; Tomas Philipson, Daniel Levin Professor of Public Policy, The University of Chicago; and Sam Pitroda, Chairman, National Innovation Council, Government of India. The session will be held from 3:45pm to 5:15pm.
NCI Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850
This workshop will include opportunities for one-on-one meetings with representatives of many of the presenting federal organizations. Please indicate your interest and top three choices below for one-on-one meetings. NCI SBIR Program Directors will also be available to meet on the afternoon of May 6. If you are interested in setting up a meeting on May 6, please mark the appropriate selection on the registration form below.
On May 6 at 6pm (EDT), NCI SBIR will host an informal, optional meet and greet at the Cafe Deluxe in the Rio Entertainment Center (9811 Washingtonian Boulevard Gaithersburg, MD 20878 – Terrace Room). Due to government restrictions, the meet and greet will be self-pay. Please RSVP below, as space for the meet and greet is limited.
Due to space limitations, priority will be given to current or recent NCI SBIR or STTR awardees, with a maximum of two (2) representatives allowed per company. This workshop is provided free of charge to attendees (excluding food and transportation expenses).
A Columbia University administrator is taking over a top post at Johns Hopkins University.
Robert C. Lieberman will take on the role of provost and senior vice president for academic affairs at Hopkins July 1. Lieberman is currently the interim dean of Columbia’s School of International and Public Affairs.
Once again we’re stepping into spring with more exciting programming in health entrepreneurship. Our Rock Health Skillshare series is open to the public and provides a unique opportunity to get an in-depth look at critical issues in health innovation, as well as a peek at Rock Health HQ in Chinatown (Dim sum anyone?). Classes generally range from $25-$30 and we provide snacks, refreshments, and ample opportunity for networking afterward. Our teachers have extensive real-world domain expertise that they are enthusiastic about sharing with others.
The Association of University Research Parks is proud to present the 18th Annual Awards of Excellence in research and science park development and practice. AURP will honor industry leaders at the 2013 International Conference in Philadelphia, Pennsylvania.
These awards bring valuable recognition to the recipients and to the industry as a whole. To nominate a park, company or an individual who has demonstrated excellence in the field, please use the below links. Each link also provides criteria and details about the award. Nominations are due by May 20, 2013.
Today, the National Venture Capital Association (NVCA) and the Medical Innovation and Competitiveness Coalition (MedIC) released Patient Capital 3.0: Confronting the Crisis and Achieving the Promise of Venture-Backed Medical Innovation. The report, which is in its third release, highlights the contribution of venture capital to medical innovation and provides perspective on the current investment environment in the U.S. for life sciences.
“Venture-backed medical innovations still provide the critical new drugs, medical devices and diagnostics that improve and save the lives of millions of Americans, but the environment for investing in these breakthroughs has become increasingly challenging,” said Jonathan Leff, Partner at Deerfield Management and Chairman of MedIC. “While the promise of science to help solve our most pressing medical problems is extraordinary, the time, cost and uncertainty involved in building start-up companies that advance fundamental medical innovations have all risen, driving some investors away from the life sciences arena in recent years. We continue to express to policymakers the importance of promoting an environment that encourages investment in medical innovation.”
Google Ventures has been backing startups through its venture capital fund since 2009 and offers a pretty diverse range of services to entrepreneurs. Here’s a look at the eight healthcare and life science businesses among its portfolio companies spanning DNA analysis, accelerated drug development, and oncology analytics.
23andMe The startup has helped make personal genetics and DNA analysis much more accessible to consumers. The company, co-founded by Anne Wojsicki, offers DNA test kits that for $99 and a little saliva help people better understand what conditions they are at risk for developing, whether they are carriers for any diseases that they could unwittingly give to their children. It can also provide information on whether people’s genetic makeup makes them particularly sensitive to certain drugs. It also uses results from user queries, with their consent, to conduct in-house research.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
The Montgomery County Department of Economic Development and our partner, BioHealth Innovation, Inc., invite you to visit us at Booth 1423, the Maryland Pavilion, during the BIO International Convention in Chicago, April 22 – 25.
Nearly 50 Montgomery County biotech companies, organizations, or public sector entities will attend. Twenty-six Maryland organizations, companies or public-sector entities will be represented in the Maryland Pavilion, Booth 1423, including the following from Montgomery County:
As part of the University of Maryland’s 26th Annual Invention of the Year Awards ceremony held at the University of Maryland Golf Course on April 16, BioHealth Innovation sweetened the pot for this year’s three award winners. BHI offered each award winner strategic consulting services on federal grants or SBIR awards – valued at $2,500 per company. The BHI Commercial Relevance Program is designed to support small businesses in commercializing their technological research efforts.
The three winning inventions were: INFORMATION SCIENCE CATEGORY: Winner: Time-Reversal Division Multiple Access for Wireless Broadband Communications Feng Han, Yu-Han Yang, Beibei Wang, Yongle Wu and K. J. Ray Liu
LIFE SCIENCE CATEGORY: Winner: A Method for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS) Eva Chin and Dapeng Chen
PHYSICAL SCIENCE CATEGORY: Winner: A Method for Rapid, Inexpensive Prototyping of Microfluidic Devices Omid Rahmanian, Donald DeVoe
Time-reversal techniques for optimizing broadband communication networks and rapid prototyping of microfluidics devices were among the Clark School of Engineering inventions recognized as the most promising new technologies at the University of Maryland Invention of the Year Awards.
The University of Maryland’s Office of Technology Commercialization (OTC) hosted the 26th Annual Invention of the Year Awards reception on Tuesday, April 16, 2013 from 4:30-6:00 pm at the University of Maryland Golf Course Club House.
On the evening of April 15 as part of the InvestMaryland Challenge Award ceremony held at MICA in Baltimore, BHI presented three awards to local companies. Boss Medical LLC of Baltimore, ConverGene LLC of Gaithersburg, and Vasoptic Medical LLC of Columbia were selected for the awards based upon their high quality products under development, which have good possibility for securing federal funding with support and assistance. Each award – valued at $2,500 – consists of consulting services from BHI on Small Business Innovation Research (SBIR) or federal funding proposals. The SBIR program is designed to support small businesses in commercializing their technological research efforts.
The NIH is the premier biomedical research center for the world. Its 27 Institutes and Centers employ approximately 18,000 employees doing a vast array of jobs, all supporting efforts for a healthy nation. For information on the NIH mission, goals, and Institutes and Centers, visit NIH Overview.
The Office of Translational Alliances and Coordination (OTAC) in the Division of Extramural Research Activities (DERA), National Heart, Lung, and Blood Institute (NHLBI) is seeking outstanding candidates for the Health Scientist Administrator (Business Development Specialist) position. The OTAC is charged with accelerating the translation of basic discoveries and innovations into new diagnostics, devices, and therapeutics, and facilitating the development of new technologies via Small Business Innovation Research (SBIR) initiatives. The Office facilitates identification of emerging areas of translational opportunities and provides functional integration by developing interdependent teams that leverage resources and intellect across the NHLBI, and with other NIH Institutes, agencies, and organizations. The OTAC enhances communication and coordination between existing programs, develops and coordinates strategic initiatives and Funding Opportunity Announcements (FOAs), and identifies and capitalizes on synergies to meet and enhance program goals.
Remedium Technologies Inc., a medical device company developing innovative products to control severe hemorrhaging, was awarded a $500,000 Small Business Innovation Research (SBIR) grant from the National Science Foundation to test the company’s sprayable foam for rapidly halting traumatic bleeding, company officials announce today.
In collaboration with Massachusetts General Hospital and the University of Maryland, Remedium will complete pre-clinical trials to evaluate the safety and efficacy of Hemogrip(TM) Foam in controlling non-compressible hemorrhaging, i.e., bleeding not accessible to direct pressure. Hemogrip(TM) is a high-pressure, sprayable foam that can expand into an injured body cavity, adhere to tissue and stop hemorrhaging within minutes during the expansion process. There are currently no hemostatic products available for treatment of non-compressible bleeds, which account for 85 percent of hemorrhage-related deaths.
Two Baltimore companies took top honors in the state’s first InvestMaryland Challenge.
GrayBug, which is developing drug delivery technology; and RedOwl Analytics, a software company, were the winners of the startup business competition’s life science and information technology categories. An LED lighting company in Cecil County, i-Lighting, won the contest’s category for general industry. Some 260 startups from 26 states, including Maryland, threw their hats in the ring.
Cleave Biosciences has added $10 million in Series A financing from new investor New Enterprise Associates, bringing its Series A total to $54 million. In the fall of 2011, Cleave raised $44 million from US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners. The company is focused on cancer drug discovery and development.
Cleave is discovering novel drugs that affect protein degradation pathways. Cancer cells frequently make an excess of proteins and hence become dependent on protein degradation for their survival. By attacking key targets in these pathways, cancer cells fail to balance this excess protein synthesis with protein degradation and can no longer survive.
The Washington region raised some $286 million in venture funding last quarter, assuming you stretch your idea of the region to include Stevensville, Md., and Blacksburg, Va. So what did we learn from three months of venture data? Here are five takeaways.
1. Deals down, dollars up: The number of deals in Q1 2013 (30 deals) was down compared with the prior quarter (36 deals), as well as Q1 2012 (45 deals), while the dollar amount was up. When 2012 went out with the crappiest quarter since 2009, the drop was attributed to the lack of big deals.
Twelve Maryland companies, including five from the Baltimore area, received a total of $83.8 million in venture capital funding in the first quarter.
That was up 20 percent from the $69.7 million that 15 Maryland firms received in first quarter 2012, according to a MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association. The report uses data from Thomson Reuters.
The Washington region raised a collective $286 million in venture capital during the first three months of 2013, thanks in large part to a $110 million financing for D.C.-based LivingSocial Inc., according to the MoneyTree report released Friday by PricewaterhouseCoopers LLP and the National Venture Capital Association.
At first blush, the number looks like good news for the region, a marked improvement from the $95 million raised in fourth quarter of 2012. Assuming the upswing holds for three more quarters, we just might be on track to fulfill Steve Case’s prediction of a $1 billion year.
The purpose of the NHLBI SBIR Phase IIB Small Market Award is to provide support to Phase II SBIR awardees developing NHLBI mission-related technologies that address a rare disease or young pediatric populations. The goal of this FOA is to de-risk these technologies so that development can continue with private funding after NHLBI support ends; therefore, applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.
Leaders of 11 top high-tech companies — including Microsoft Corp. and Intel Corp. — signed a partnership agreement Monday with a fairly new Rockville-based center on cybersecurity, pledging to work together to further that growing industry.
The companies will help the National Cybersecurity Center of Excellence — an agency formed a year ago by the federal National Institute of Standards and Technology, Montgomery County and the state of Maryland — develop leading-edge technology to combat hackers and other cyber-criminals, officials said.
New York City nonprofit Venture for America, which provides entrepreneurship training for recent college graduates, is adding Baltimore to its roster of cities this year.
Venture was founded in 2011 to encourage entrepreneurship through practical experience. It officially launched last year in five cities: Detroit, Cincinnati, New Orleans, Las Vegas and Providence, Rhode Island. This year, Baltimore and Cleveland are on board.
These infographics from DrugPatentWatch.com and BiologicPatentWatch.com track innovation and patent activity in the pharmaceutical and biotechnology industries:
President Obama has challenged us all to help win the future by out-educating, out-innovating, and out-building our competitors in the 21st century.
Know someone who is doing extraordinary things to make a difference in your community? Nominate them to be a Champion of Change. We’ll consider your nominations as we feature people who are bringing about change in their communities on the White House website to share their ideas on how to win the future.
Entrepreneurs in any industry need to start with a big idea – and a big tolerance for risk. But in health care, startups often need to take on a unique set of regulatory hurdles, complex systems and entrenched ways of getting things done to successfully build and scale.
At the TEDMED conference Thursday, a few of the industry’s most seasoned entrepreneurs and investors gave emerging startups a dose of advice. Here are a few of their tips:
U.S. Small Business Administration chief Karen Mills was in Baltimore on Thursday to highlight the agency’s education program for entrepreneurs.
Baltimore was one of the first cities to launch SBA’s Emerging Leaders program, formerly called E200 back in 2008. The program offers a seven-month course in which a select group of business owners learn the skills they need to grow their companies.
There’s been discussion recently about a lack of life science venture capital enthusiasm for emerging digital health companies. I happen to feel that this concern is misplaced. I engaged industry and opinion leaders on this subject plus have my own thoughts on the digital health funding environment.
In his latest article in Forbes, contributor David Shaywitz characterizes life science venture capitalists as just “kicking tires” on potential digital health investments, citing fears from prominent investor Nimesh Shah that innovations in digital health are “merely a bubble,” and that these firms lack a “real biz model.”
The Universities at Shady Grove (USG) and the Rockville Institute come together annually to offer this dynamic, interactive seminar series. The series stimulates an exchange of ideas among practitioners, researchers, policymakers, students, and the public at large about contemporary social issues. Seminars are free and open to the public.
The U.S. market for remote patient monitoring, valued at $104.5 million in 2012, is forecasted to reach $296.5 million by 2019, a compound annual growth rate of 16 percent, according to a new report from GBI Research.
Chronic diseases represent an overwhelming burden for healthcare systems in developed countries, due to increasingly elderly populations, and a clear need exists for remote patient monitoring to help lift the load off stretched healthcare resources, according to the report Remote Patient Monitoring Market to 2019 – Potential to Reduce Healthcare Cost Burden and Improve Quality of Care to Drive Future Growth.
With nearly half a billion dollars raised in venture capital funding for health information technology, the first three months of 2013 represented a “record quarter,” according to Mercom Capital Group.
Some $493 million was raised industry-wide, according to Mercom’s 2013 Healthcare IT Funding and M&A Report, in twice as many deals as the previous quarter (104, up from 51). There were nearly four times as many early stage deals – 42, up from 14 – compared to the fourth quarter of 2012.
The University of Maryland, Baltimore County and Northrop Grumman Corp. last month expanded their Cync cybersecurity program with three new companies, including the program’s first international one. The three firms joined the five companies currently at bwtech@UMBC Research and Technology Park in Catonsville.
Eight years of work, thousands of researchers around the world, $1 billion spent — and finally it was done. On April 14, 2003, a decade ago this week, scientists announced that they had completed the Human Genome Project, compiling a list of the three billion letters of genetic code that make up what they considered to be a sort of everyperson’s DNA.
The need for innovation in healthcare has arguably never been greater. A range of factors, from aging world populations to rising standards of living in developing countries, are poised to drive long-run demand for innovative drugs, devices and medical technologies that can improve outcomes and reduce costs.
Ironically, however, funding for healthcare innovation remains in short supply. As industry participants are keenly aware, life science venture capital financing – which has played a critical role in helping translate research ideas into commercially useful medical technologies – is becoming increasingly scarce.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
On the evening of April 15 as part of the InvestMaryland Challenge Award ceremony held at MICA in Baltimore, BHI presented three awards to local companies. Boss Medical LLC of Baltimore, ConverGene LLC of Gaithersburg, and Vasoptic Medical LLC of Columbia were selected for the awards based upon their high quality products under development, which have good possibility for securing federal funding with support and assistance. Each award – valued at $2,500 – consists of consulting services from BHI on Small Business Innovation Research (SBIR) or federal funding proposals. The SBIR program is designed to support small businesses in commercializing their technological research efforts.
Richard Bendis will speak at the Translational Research Forum during the 2013 BIO International Convention in Chicago. During the forum, speakers will address issues with current translational research models, explore new funding and collaboration opportunities, evaluate how to apply them to federal, academic, and private institutions. The session will take place Monday, April 22, from 4:35 p.m. – 5:25 p.m.
Location: Morgan, Lewis & Bockius Conference Center, 1111 Pennsylvania Ave., NW Washington, DC 20004-2541
National Brain Tumor Society is bringing together brain tumor researchers and industry executives to discuss how to move research from bench to bedside.
Biophrama executives and VC investors will share their criteria for investment and licensing of academic research.
Panelists include:
Lauren Abrey Global Development Team Lead, Genetech/Roche
Neil Exter Partner, Third Rock
Brian Gallagher Partner, SROne
Michael Glutch Managing Director, Medimmune Ventures
Perry Nisen Senior VP of Science Transactions, Pfizer
Nation Brain Tumor Society-funded researchers will present brain tumor drug candidates ready for early stage investment and/or licensing.
Friday, May 24 • 12:00 – 2:00 pm • Marriott Bethesda North Conference Center
Join the Montgomery County Department of Economic Development to celebrate small businesses. Attend the inaugural Small Business Awards program.
The award luncheon will provide countless opportunities to show your appreciation for the estimated 33,000 small businesses of Montgomery County—businesses that contribute directly to the strength of the area’s economy. Eight awards will be presented to eight distinct companies.
Cleave Biosciences has added $10 million in Series A financing from new investor New Enterprise Associates, bringing its Series A total to $54 million. In the fall of 2011, Cleave raised $44 million from US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners. The company is focused on cancer drug discovery and development.
Cleave is discovering novel drugs that affect protein degradation pathways. Cancer cells frequently make an excess of proteins and hence become dependent on protein degradation for their survival. By attacking key targets in these pathways, cancer cells fail to balance this excess protein synthesis with protein degradation and can no longer survive.
When he was young, Daniel J. Abdun-Nabi wasn’t all that interested in subjects like biology. He gravitated toward political science and the law in college, and worked for the federal Securities and Exchange Commission soon after graduating.
“I went out of my office and saw the Capitol. It was awe-inspiring,” Abdun-Nabi, 58, who grew up near Boston, said of working in Washington, D.C.
David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to hunt down the best in vivo-stage assets in academia, biopharma and the nonprofits, assemble them in a portfolio of rare disease therapies and mold them into pipeline programs that can be spun out into a slate of new biotech companies.
NEA’s high-profile biotech partner Mott–who helmed MedImmune until AstraZeneca ($AZN) came along and scooped it up for $15.6 billion–partnered with Pfizer Ventures and gained the support of Alexandria Real Estate Equities in piecing together the initial $16 million in startup funds for the newly coined Cambridge, MA-based Cydan.
GlaxoSmithKline, Britain’s biggest drugmaker, is placing a small but important bet on a new way of treating diseases by targeting electrical signals in the body.
The company said on Wednesday it would offer a $1 million prize to stimulate innovation in the field, as well as funding up to 40 researchers working in external laboratories.
The Global Virus Network plans to move its headquarters to the University of Maryland BioPark in Baltimore, officials announced Thursday.
Emerging pandemic viral threats and current viral killers are a worldwide problem. For this reason, the nonprofit GVN brings together the top medical virologists from more than 30 institutions in 21 countries, to promote international collaborative research, education and advocacy.
Pluristem Therapeutics (NASDSQ: PSTI) announced today that following favorable preclinical studies, United Therapeutics Corporation received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem’s PLX-PAD cells for PAH.
PAH is characterized by abnormally high blood pressure in the arteries of the lungs and leads to an increased workload on the right side of the heart.
Pieris AG and The Sanofi Group have jointly agreed to expand their ongoing discovery and development partnership to include a novel multispecific Anticalin® program. Under the existing framework of the 2010 agreement, the new program will entitle Pieris to an upfront payment from Sanofi and committed research funding as well as payments for the achievement of research, preclinical, regulatory and commercial milestones. Specific financial terms were not disclosed.
A test that detects human papillomavirus, a virus directly related to cervical cancer, has hit the market following approval by the China Food and Drug Administration.
“The careHPV test is faster, better and cheaper,” says Qiao Youlin, a respected epidemiologist, who headed a research project into the development of careHPV between 2003 and 2008. The research was assisted by the Bill & Melinda Gates Foundation, which contributed $13 million to the project.
Company: MedImmune Booth/Stand: 3344 Event: 2013 BIO International ConventionApr 22 – 25 2013 Chicago IL US
About MedImmune
MedImmune is the worldwide biologics research and development arm of AstraZeneca a global innovation-driven biopharmaceutical business that focuses on the discovery development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas including respiratory inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. MedImmune has approximately 2500 employees globally with its headquarters located in Gaithersburg Md. one of AstraZeneca’s three global R&D centers. For more information please visit www.medimmune.com.
When engineers at this university learned of a Baltimore neurosurgeon’s struggle to operate on sensitive parts of the brain, they designed a tiny robot to maneuver around more precisely than instruments held by a human hand during surgery — something Loh said never would have happened if the neurosurgeon and robotic engineers had not met. Now, one year into the partnership, the universities have launched a collaborative public health school, developed a joint biomedical informatics and bioimaging center and created a research and innovation program.
“When you have a formal structure for a partnership and encourage people to talk to each other, this is what the partnership between the universities is all about,” Loh said. “They have the problems; we have the solutions.”
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, announced the finalists for its 25th Annual Dinner and Awards Celebration. Winners will be announced at the awards dinner on May 16 at the Bethesda North Marriott Hotel and Conference Center.
“This year’s finalists are a testament to the ingenuity and vibrancy of Maryland’s technology and life sciences community,” said Larry Letow, TCM’s chairman. “Their innovations advance the cause of a healthier, safer world while fostering job creation and prosperity here in Maryland. Simply put, Maryland’s tech and biotech companies are essential to our long-term economic growth. The TCM’s Awards Celebration is a great way to celebrate our members’ tremendous achievements to date and the bright future that lies ahead.”
The Tech Council of Maryland (TCM), Maryland’s largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today commended state policy makers for advancing key priorities for the tech community during this year’s legislative session. The 2013 session concluded on Tuesday.
“Maryland’s policy makers delivered on our biggest priorities: stronger incentives for R&D and biotechnology, new incentives for cybersecurity investments, and corporate tax code certainty for employers,” said Larry Letow, TCM’s chairman. “We have many strong advocates in Annapolis who understand that Maryland’s technology and biotechnology companies are catalysts for innovation, job growth and prosperity.”
One of the world’s top physicians, Dr. Eric Topol, has a prescription that could improve your family’s health and make medical care cheaper. The cardiologist claims that the key is the smartphone. Topol has become the foremost expert in the exploding field of wireless medicine. Dr. Nancy Snyderman reports.
I launched a literary magazine in college. I actually thought that was a good idea. After a few too many 16-hour days of hustling ads and desperately scrounging for content, my grades tanked and my blood pressure skyrocketed. I learned that special kind of panic that comes from trying to execute on the inflated ambitions of a 20-year-old. The process consumed everything. (For the record, I regret nothing.)
My point is: The university setting is great for being entrepreneurial. But it takes organization and drive to hold it all together — something I realized I didn’t have. At least some of these young founders do.
Nominate your best startups to present to a select group of invitation-only investors and Global 1000 companies as part of the Virtual Startups Showcase (VSS) and the Exits Startups Showcase + Conference in San Francisco
NOMINATION DEADLINES
For University Startups: Friday, April 26, 2013
For Accelerator, Angel Investor and VC Portfolio Companies: Friday, June 14, 2013
The National Council on Entrepreneurial Tech Transfer (NCET2) asks universities, accelerators, Angel investors and VC’s to nominate their best startups and have them present to a select group of invitation-only investors and Global 1000 companies.
The need for innovation in healthcare has arguably never been greater. A range of factors, from aging world populations to rising standards of living in developing countries, are poised to drive long-run demand for innovative drugs, devices and medical technologies that can improve outcomes and reduce costs.
Ironically, however, funding for healthcare innovation remains in short supply. As industry participants are keenly aware, life science venture capital financing – which has played a critical role in helping translate research ideas into commercially useful medical technologies – is becoming increasingly scarce.
HHS Secretary Kathleen Sebelius joins Ellen Murray, the Assistant Secretary for Financial Resources (ASFR), and HHS agency leaders to announce the President’s HHS budget for Fiscal Year 2014.
The University of Maryland (UM) BioPark announced today that the Global Virus Network (GVN) is the Park’s newest tenant. The GVN is a non-profit organization comprised of the top medical virologist in more than 30 institutions spanning 21 nations – and growing. GVN’s mission is to combat emerging pandemic viral threats and current viral killers through international collaborative research, training the next generation of medical virologist, education and advocacy.
Said Jim Hughes, President, Research Park Corporation, University of Maryland Baltimore, “It’s exciting for the UM BioPark to include the prestigious Global Virus Network as one of our tenants. We are also pleased to be able to offer GVN continued close proximity to its Scientific Director, Co-Founder, and world-renowned virus researcher Dr. Robert Gallo from the UM School of Medicine, whose Institute of Human Virology is located conveniently just down the street from the GVN’s new BioPark headquarters.”
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Pictured: Rich Bendis, BHI; Arkesh Mehta, Chikujee Therapeutics; Stephen Yoder, Pieras AG; Rick Soni, Rexahn Pharmaceuticals
Growlers was “abuzz” on March 20 with a large and diverse gathering of biotech professionals attending the monthly BioBuzz networking event. BHI CEO Rich Bendis welcomed the crowd and talked about the latest happenings at BHI. According to Andrew Eckert, “We received a lot of positive feedback on the location and found a number of folks were interested in speaking to somebody from BHI. I’m pretty confident this was one of the largest, if not THE largest turnout ever for a BioBuzz event.”
BioBuzz is working to build a stronger community by bringing the biotech workforce out of the labs to culture relationships, instead of just cells.
On April 2, BHI invited a team of NIH Office of Technology Transfer interns working with BHI EIR Todd Chappell for a Social Meeting. Also in attendance were two guest speakers. Bart Kus, Senior Manager of Portfolio Management MedImmune, spoke about his career track from the lab into business development. Errol Levy, EU Diplomat (Research and Innovation Counsellor) for the European Commission talked about opportunities in Europe and the upcoming Destination Europe Conference on April 11 in DC. It was a great event for all who attended.
Maryland has invested $500,000 in Cytomedix Inc., a regenerative medicine company in Gaithersburg.
The investment was made through the state’s Maryland Venture Fund and InvestMaryland program. The state said the money is part of a $27.5 million fundraising round by Cytomedix (OTC: CMXI) that will result in the company adding 13 new employees to its current staff of 55.
Tom Sadowski, President and CEO, of the Economic Alliance of Greater Baltimore has been appointed to UMBC’s Public Policy External Advisory Board. Created in 2003, the External Advisory Board provides advice and guidance to UMBC’s Department of Public Policy and the Maryland Institute for Policy Analysis and Research (MIPAR). An important part of their mission is to bring the University’s public policy expertise to bear on the concerns of the communities they serve.
GlaxoSmithKline is trying to expand the market for its Benlysta drug beyond lupus by launching a major study of the medicine as a treatment for a serious blood vessel disorder.
GSK acquired full control of Benlysta when it bought Human Genome Sciences for $3 billion last year. Current sales of the drug are modest, at 70 million pounds ($106 million) in 2012, but GSK hopes it will become a major seller.
BioMed Realty Adds 1.6 Million Square Foot Portfolio & Expands University / Research Institution Segment to 18% of Annualized Base Rents
BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a definitive agreement to merge with Wexford Science & Technology, LLC, a subsidiary of Wexford Equities, LLC, furthering BioMed Realty’s position as the leading provider of real estate to the life science industry. Wexford Science & Technology is a private real estate investment and development company that owns and develops institutional quality life science real estate for academic and medical research organizations, and that boasts well-regarded skills for urban development and redevelopment of life science real estate. The aggregate consideration for Wexford Science & Technology is approximately $640 million, excluding transaction costs and subject to adjustment based on working capital levels and construction and development costs incurred prior to closing. Wexford Science & Technology will operate as a wholly owned subsidiary of BioMed Realty.
The Maryland Department of Business and Economic Development has named three finalists in three separate categories of the final round of the InvestMaryland Challenge. The winning companies, to be announced April 15, will receive $100,000 in top prizes and $125,000 in cash and in-kind awards as part of the Maryland Venture Fund’s first business competition.
InvestMaryland is a state venture capital initiative managed by DBED and the state-run Maryland Venture Fund. The initiative raised $84 million through a tax credit auction in 2012 to invest in startup companies.
AstraZeneca ‘s ( AZN ) worldwide biologics research and development (R&D) unit, MedImmune recently acquired AlphaCore Pharma, a biotechnology company based in Michigan. Financial terms of the deal were not disclosed by the companies.
We note that the acquisition of AlphaCore Pharma adds ACP-501 (a recombinant human lecithin-cholesterol acyltransferase/ LCAT enzyme) to AstraZeneca’s pipeline. The candidate is being developed for acute coronary syndromes (ACS) and other high-risk atherosclerosis conditions for the rapid removal of tissue cholesterol.
Johns Hopkins researcher Se-Jin Lee was named Wednesday as the 2013 recipient of the Ho-Am Prize in Medicine, which recognizes outstanding accomplishments in medical research that pave the way to conquering disease. It is awarded each year to an ethnic Korean and is sometimes referred to as “Korea’s Nobel.”
Lee is best known for his discovery of myostatin, a hormone that regulates muscle mass, and related work that lays the foundation for new therapies for conditions such as muscle wasting and muscular dystrophy.
Those who join MedImmune feel a sense of ownership about their future. They thrive with a recognized leader in the biotechnology industry and the wholly-owned subsidiary of AstraZeneca plc.
Here, you will join passionate professionals who advance science, technology and medicine to develop products designed to help people live better lives. You will excel in an environment characterized by respect, integrity and growth opportunities…that encourages both individual contribution and collaborative entrepreneurial thinking. Our products and/or product candidates are designed to address areas of need in infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. Explore a MedImmune career as we strive to better more lives, more often, around the world.
The Maryland House of Delegates has passed a measure to adjust how money from a state venture capital fund can be used to try to make it more effective.
The House voted 107-25 on Saturday for the bill. That sends it to the Senate to consider amendments delegates made to the measure.
WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science
Are you nearing completion of your graduate degree or fellowship, and wondering how you’re going to transition into the healthcare industry? Do you get nervous thinking about how to identify the career in healthcare that fits you best? Do you wish you had a mentor to discuss these concerns with? If so, then you are the perfect candidate to apply for the WIScience Scholarship: The Premier Catalyst for Developing Women Leaders in Science offered by the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA).
President Obama unveils a bold new research initiative designed to revolutionize our understanding of the human brain, and discusses the importance of investing in American innovation to create jobs and strengthen our economy. April 2, 2013.
Since the passage of the Jumpstart Our Business Startups (JOBS) Act (H.R. 3606) last year, the financial and medical press has been buzzing about the potential for crowdfunding to revolutionize fundraising for early-stage biotech companies. Even more recently, a portal that is exclusively dedicated to crowdfunding biotech and healthcare start-ups launched at medstartr.com. Although there may be reason for biotech entrepreneurs to be excited about crowdfunding, there are significant limitations and risks to this approach as well.
There’s an interesting trend I’ve noticed with at least one healthcare accelerator I have been tracking. The members of the startups for the most part have increasingly more industry experience and seem more adept at finding pain points and delivering a workable solution to members of the healthcare ecosystem. And if the successes of Blueprint Health’s latest graduating class are anything to go by, healthcare companies are getting increasingly receptive to working with startups that can help them address some of the demands of the Affordable Care Act and some of its impacts with more innovative solutions.
Seeking to maximize ongoing research, innovative ideas and revenue-generating opportunities, more schools are creating entrepreneur-in-residence programs — and letting the experts do the work.
With millions of dollars of research funding and teams of experts at their disposal, more universities are seeking ways to turn research breakthroughs into business opportunities.
DreamIt Health, a new Philadelphia-based, health-focused chapter of incubator DreamIt Ventures, has announced its first class of ten startups. Independence Blue Cross (IBC) and Penn Medicine are sponsoring the class and Venturef0rth is providing the working space for the companies. The new accelerator was launched in December 2012.
The startups will be provided with up to $50,000 in funding, office space, mentoring, and resources for developing and testing health-related products. The incubator will last four months, and companies will receive coaching from both entrepreneurs and health care executives. DreamIt Ventures has launched 80 companies over the past four years, including one health-related startup, 1DocWay. Supporting sponsors include global professional services company Towers Watson, and law firms Morgan Lewis, and Pepper Hamilton.
Among 400 applications from 22 countries, 13 early stage healthcare companies have been chosen for a three-year entrepreneurship class run by StartUp Health and GE, according to a statement from the companies. The class members will each be assigned a GE mentor who matches their business model and get access to the resources the Fortune 50 company can wield to help scale their consumer health innovations. That could include working with GE Healthymagination, GE Healthcare, GE Capital, or some of its business units, depending on the members’ specific needs.
Digital health incubator Rock Health released data today that shows an increase in funding for med-tech startups in the first quarter of 2013.
Thirty-seven health deals were valued at a total of $365 million, which is 35 percent higher than the first quarter of 2012, “suggesting that 2013 will be another record year for the digital health industry,” the blog post reads.
Philadelphia has reached a milestone in its efforts to be recognized as a healthcare and life sciences hub with the start of its first health IT accelerator.
DreamIt Health’s inaugural class includes 10 startups. The four-month program co-sponsored by Independence Blue Cross and Penn Medicine includes members seeking to develop tools for healthcare providers to speed up diagnoses and improve outcomes.
GlaxoSmithKline ( GSK ) recently announced that it has initiated a phase III study to evaluate the use of Benlysta (belimumab) in patients suffering from anti-neutrophil cytoplasmic antibodies (ANCA) positive vasculitis.
The multi-centre, randomized, double-blind phase III study will assess the efficacy and safety profile of Benlysta in combination with azathioprine as a maintenance therapy in ANCA positive vasculitis patients.
A big-data revolution is under way in health care. Start with the vastly increased supply of information. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, while payors and providers have digitized their patient records. Meanwhile, the US federal government and other public stakeholders have been opening their vast stores of health-care knowledge, including data from clinical trials and information on patients covered under public insurance programs. In parallel, recent technical advances have made it easier to collect and analyze information from multiple sources—a major benefit in health care, since data for a single patient may come from various payors, hospitals, laboratories, and physician offices.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.
“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.
“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.
The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.
Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:
About BioHealth Innovation, Inc. BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
Congratulations to Elaine Amir! Elaine, executive director of the Montgomery County Campus of Johns Hopkins University, was named to The Daily Record’s 2013 list of Maryland’s Top 100 Women.
The announcement brought kudos from JHU interim provost Jonathan Bagger.
BioMed Realty Adds 1.6 Million Square Foot Portfolio & Expands University / Research Institution Segment to 18% of Annualized Base Rents
BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it has entered into a definitive agreement to merge with Wexford Science & Technology, LLC, a subsidiary of Wexford Equities, LLC, furthering BioMed Realty’s position as the leading provider of real estate to the life science industry. Wexford Science & Technology is a private real estate investment and development company that owns and develops institutional quality life science real estate for academic and medical research organizations, and that boasts well-regarded skills for urban development and redevelopment of life science real estate. The aggregate consideration for Wexford Science & Technology is approximately $640 million, excluding transaction costs and subject to adjustment based on working capital levels and construction and development costs incurred prior to closing. Wexford Science & Technology will operate as a wholly owned subsidiary of BioMed Realty.
The Maryland Venture Fund has awarded $300,000 to Adlyfe, a Rockville diagnostic test developer, as part of the state’s InvestMaryland program.
Adlyfe, which is developing an early detection test for Alzheimer’s disease, is also receiving a $200,000 grant from the Maryland Biotechnology Center.
Emergent BioSolutions, Inc., a global specialty pharmaceutical company, is generating fresh ideas from Michigan State University students at its Lansing location to improve operations.
Emergent BioSolutions, the Roscommon-based Lear Corp., the Saginaw-based Mistequay Group, Ltd. and approximately five other companies hosted more than 20 undergraduate and graduate business and engineering students on various projects. The initiative is the brainchild of Bill Demmer, the CEO of the Lansing-based Demmer Corp., who donated $5 million to the university to create the Marnie Demmer Center for Business Transformation in late 2011, MLive.com reports.
Sure, New Enterprise Associates is much, much bigger than most venture capital firms. And not all of their deals fall neatly into what we think of as traditional Series A-B-C venture.
NEA invests in private hospital systems in China. It does the occasional PIPE deal. It does big-ticket “growth” fundings that look a whole hell of a lot like private equity.
But NEA is definitely not a private equity firm, as it is here described in The Wall Street Journal.
Two announcements on Monday and Thursday of last week signaled a fundamental strategic and physical shift for biopharma giant AstraZeneca, including the establishment of a new corporate headquarters in a new UK location; the shift of small molecule and biologics R&D to three strategic centers around the world; and an eventual overall headcount reduction of 5,050 between now and the end of 2016.
On Monday, March 18, the company announced its intent to focus the R&D in three places, and to fully implement these plans by 2016:
As the CEO of Pulse8, John Criswell works with health insurance exchanges and long-term care facilities on big data and analytics, which gives him a purview into the back-end integration required for states and the federal government to setup HIXs. Yet, he’s optimistic that the gvoernment will meet the October 1, 2013 deadline.
Government Health IT Editor Tom Sullivan spoke with Criswell about the complexity of standing up HIXs, how the exchanges might fare come October, and the overarching opportunities that both HIX and health information exchanges will create as they amass mammoth data sets.
Monday, April 15th 5:30 – 8:30 p.m. at MICA’s Brown Center
After months of submitting business plans, scoring applications, developing special awards and partnering with us, it’s time to celebrate entrepreneurship! Please join us April 15th at Maryland Institute College of Art’s Brown Center as we announce the top three $100K winners.
Tech entrepreneurs will soon find a new home at Innovation Crossroads, the Eastern Shore’s first, full-service business incubator.
Gov. Martin O’Malley and the department of public works recently approved $1.2 million in funding from the Maryland Department of Business and Economic Development for construction of the incubator, the Dorchester County Council announced on Tuesday.
Innovation Crossroads is the planned anchor tenant of the newly constructed Cambridge-based Regional Technology Park.
“Transformation” is the best description of what is happening in health care right now. We are seeing historic changes in how health care is administered in the United States—with increased focus on quality of care versus just paying for a service. We are seeing changes in how people can enroll in health insurance—with the upcoming establishment of a new market place that will help more people get insured in this country than ever before. And, we are seeing changes in how people understand and make decisions about their own health—with an increasing number of tools and services becoming available to help individuals access health information and manage their own personal health data.
The Congressional hearings debating the regulatory framework for mobile health devices and apps made me think about how we view mobile health apps and the criteria we use to determine what makes some better than others.
And as we all think in terms of the NCAA college basketball tournament around this time, I thought we would do a mini tournament using mobile health apps.
As we come to the close of Q1 of 2013, LSN has compiled some insight into three of the hottest subsectors being targeted by investors in the medical technology space. New technologies are surfacing that are changing treatment philosophies, and more importantly, medtech is attracting a whole new class of investors such as corporate venture from the consumer electronics, digital media, and telecom space. Here are the three trend areas that are changing the world from the medtech investor perspective:
This the title [paraphrased] of a keynote given last week by Jonathon Bush, the CEO of AthenaHealth, at the Xconomy Mobile Madness conference in Cambridge, Ma. What follows are my notes from the speech. The ideas are Jonathon’s. I really like what he’s saying and mostly agree, and he puts it very well.
AthenaHealth’s base business is medical practice billing in the cloud. This is an example of technology-enabled transformation of the health care business system, which we believe will be a big opportunity for entrepreneurs going forward. Founded in 1997, AthenaHealth is now a successful public company (ATHN).*
A week after the Congressional hearings discussed how the US Food and Drug Administration’s impending regulatory guidelines (expected by October) will impact mobile health apps, aspiring and current digital health entrepreneurs may be rethinking their path. In a report dubbed “FDA 101,” health startup accelerator Rock Health has compiled a handy report to help digital health entrepreneurs assess whether their mobile health apps would be classified as medical devices by the FDA and require 510(k) clearance.
Some of the pressure to clear the waters has come from technology developments that have simply outpaced the regulatory environment. Another is that provisions of health care reform call for making greater use ofremote monitoring, to reduce healthcare costs. Providers are pretty keen to reduce costs where they can as well. Remote monitoring would be particularly helpful when it comes to patients with chronic conditions, such as congestive heart failure or diabetes or both, so they can have shorter hospital stays and care managers can be alerted for any changes in their vital signs.
President Barack Obama’s top healthcare adviser acknowledged on Tuesday that costs could rise in the individual health insurance market, particularly for men and younger people, because of the landmark 2010 healthcare restructuring due to take effect next year.
U.S. Health and Human Services Secretary Kathleen Sebelius said definitive data on costs will not be available until later this year when private health plans become authorized to sell federally subsidized coverage on new state-based online marketplaces, known as exchanges.
Many of the changes in the healthcare industry outlined by the Affordable Care Act and HITECH Act call for shifting to healthcare IT for helping physician practices run more efficiently to helping guide clinical outcomes. But the shift from paper based to digital records isn’t just happening among providers. It is carrying over into other industries that healthcare intersects such as pharmaceuticals, medical devices and more robust collaborations with payers.
Andrew Khouri of Quaker Partners, who also mentors Blueprint Health accelerator companies, highlighted some needs in healthcare that are creating interesting investment opportunities and some investment trends at a recent event at the University City Science Center. Khouri acknowledged the “industry is in turmoil” because there’s uncertainty about how the changes will work in practice from the transformation of payment models to setting up health insurance exchanges. But there’s so much momentum to reduce costs and improve outcomes that there is a lot of opportunity.
The Series A crunch has left the realm of Bigfoot and Nessie and is entering the realm of truth, at least according to Fenwick & West.
The law firm released the results of its 2012 Seed Financing Survey today, which found that the number of startups obtaining Series A financing after a seed round declined significantly in 2012.
As expected, the third and final (for now, at least) congressional hearing focused on the FDA’s regulation of mobile medical apps was the only one that provided new information for those already well-versed in mobile health. While the past two days of testimonies likely helped members of Congress better understand the concerns of those working or lobbying for the healthcare and technology industries, those testimonies did not reveal anything new about what was actually going on at the FDA.
This morning the FDA’s Christy Foreman, who serves as the Director of the Office of Device Evaluation at the Center for Devices and Radiological Health, shared a number of insights about mobile medical app regulation that before today had not been revealed. Here are five things we learned from the FDA’s testimony during the congressional hearing today:
Why not explore what’s to gain from crowdfunding when there’s nothing to lose? MedStartr’s co-founder and CEO Alex Fair explains.
Alex Fair, Co-Founder & CEO of MedStartr Thinking about joining the crowd? We know, your mother probably told you not to get mixed up with the wrong kind. But according to MedStartr’s Alex Fair, there’s a lot right with the mob mentality growing among today’s entrepreneurs; crowd communities are creating equitable springboards for promising startups. That’s right, we’re talking about crowdfunding. After all, there is strength in numbers— especially from those that come with dollar signs.
No action is good action. At least for online investment platform the Funders Club that today received a ‘no-action letter’ from the SEC stating that it will not recommend enforcement action.
The letter is a green light for the FundersClub and validation that its investment model is legal. The news is significant for the venture capital and finance industries, as well as startups looking for more flexible methods of fundraising.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.
“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.
“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.
The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.
Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:
About BioHealth Innovation, Inc. BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
MedImmune’s Gaithersburg headquarters will gain 300 new jobs under a broader U.S. consolidation by parent company AstraZeneca PLC, the companies announced Monday.
The move follows management changes at both companies. Pascal Soriot was named AstraZeneca CEO in August, and early this year carried out a leadership shuffle that included installing Bahija Jallal as MedImmune’s new chief. She replaces Peter Greenleaf, who is heading AZ’s Latin American unit.
Demonstrating its deep interest in the future of rare diseases, Pfizer ($PFE) has signed on to partner with Gaithersburg, MD-based GlycoMimetics on its lead drug program for sickle cell disease, promising up to $340 million in a broad array of milestones and an unspecified upfront payment. The partnership will bring in Pfizer on the development of GMI-1070, an inflammation inhibitor that researchers have been studying in a Phase II trial for the painful vaso-occlusive crises that threaten the organs of sickle cell patients.
In a demonstration of the booming field of genomic research, investors have pumped $21.3 million into a company that makes and manufactures genome-wide research tools and services.
OriGene Technologies said its Series C was led by Chinese venture firm Qiming Venture Partners and Kleiner Perkins Caufield Byers China, with participation from previous investor IDG-Accel, a China-focused private equity firm.
Montgomery County is implementing a Smart Growth Initiative to build on the area’s strengths in biotechnology and health care in a way that will create mixed-use neighborhoods and walkable new housing developments.
The three places where most of this new construction will occur are the Greater Seneca Science Corridor along Route 28, the White Oak Science Gateway west of Gaithersburg and the White Flint expansion along Rockville Pike. Each project possesses the core elements of walkability, rapid transit options and mixed-use development.
The outsourcing of information technology jobs being seen at Bethesda hotel giant Marriott International is not likely a harbinger of more to come, technology and business officials say.
Marriott executives said this week they are cutting “hundreds” of jobs and reorganizing the company’s information technology department in Bethesda in response to a more competitive global business environment. Layoffs are expected to start as early as next month.
Sequoia Holdings, Inc., a leading provider of software development solutions to the U.S. Intelligence Community, is teaming up with Washington DC area private equity and venture capital firms to launch an accelerator focusing on new cyber security and analytic startups. Based in Reston, VA, Sequoia Apps, LLC will concentrate on helping local entrepreneurs create and launch successful startups and connect them to DC area venture capital, private equity and angel investors for additional funding opportunities.
In addition to seed funding, mentoring and coaching, Sequoia Apps is designed to help capitalize on the successful past performance and unique skill sets of all IC focused developers and engineers and help build viable and disruptive commercial applications. “Sequoia Apps is a great example of how companies can leverage the successful past performance of their employees and connect them to the intellectual and financial scene of the DC startup community,” said T. Richard Stroupe, Jr. Sequoia Holdings co-founder. “For years, our development staff has designed and built world class applications for various IC customers, and now we would like to create a new disruptive platform to invest in those engineers in order to help them achieve similar success in emerging markets”.
In a move sure to inflame the libertarian blogosphere, a presidential ethics commission recommended today that researchers study the effects of anthrax vaccine on children.
The Presidential Commission for the Study of Bioethical Issues said researchers must first overcome numerous challenges before testing a pediatric version of the anthrax vaccine, intended to protect the American population from a potential bio-terrorist attack.
Startup Maryland (www.startupmd.org), a regional initiative of the national Startup America Partnership (www.s.co), today announced the Raise Your Game initiative to provide the Maryland entrepreneur community with a structured educational program designed to help startup CEOs and founders understand and employ the building blocks of strong startups and startup communities.
Development of the Raise Your Game program and curriculum was led by Startup Maryland Entrepreneur Champions Sam Polakoff, (president of TBB Global Logistics), Gregg Smith (CEO of Koolspan) and Startup Maryland co-chair Michael Binko (CEO of kloudtrack®). Beginning in July of 2013, Raise Your Game will consist of a 6 month educational “bootcamp” program emphasizing the critical components of building successful companies.
This week the US House of Representatives’ Energy and Commerce Committee is hosting a three-day series of hearings focused mostly on the FDA regulation of mobile medical apps. As of this writing two hearings have taken place, one held by the Communications and Technology subcommittee on Tuesday and another held by the Health subcommittee on Wednesday, but what could be the main event is set to take place early Thursday morning as representatives from ONC and FDA face questions from Congress.
Wednesday evening the testimonies for both the FDA’s Director of the Office of Device Evaluation Center for Devices and Radiological Health, Christy Foreman and the ONC’s National Coordinator Dr. Farzad Mostashari are now posted on the committee’s site. Neither includes any real surprises, but Foreman’s reiterates much of the FDA’s draft guidance and includes a note that any questions about the medical device tax should be directed at the IRS. The real discussion will come when Foreman and Mostashari answer the representatives questions after they read their prepared remarks.
Montgomery County has a plan to market itself as a business and tourist destination to a particularly captive audience — one traveling at 30,000 feet.
During April, air travelers on some 1,700 U.S. Airways flights, and select American Airlines flights (for business first class travelers only), will be targeted with videos promoting Montgomery County as a place to relocate a business, to live, work and play.
Cupid’s Cup Business & Innovation Showcase and Competition is where you’ll find the coolest innovations from the UMD campus and our region all under one roof. Pick the brains of entrepreneurs from all kinds of businesses. Take a break from the the dining halls and your usual lunch spots and visit the food trucks. Get to the competition early to score one of our limited-edition t-shirts. And definitely stay to watch our competitors duke it out in front of Under Armour Founder Kevin Plank.
Please join us to learn more about the uniqueness of Aeras: the product development partnership model, funding, center of excellence and CMO capabilities. Aeras, a not-for-profit, product development organization focused on developing safe, effective vaccines to prevent TB and ensuring they will be available and affordable for the populations that most need them.
A certain song has been running through my head the past few days. Lately, it strikes me as an anthem of sorts for biotech venture capital in 2013.
It’s Fleetwood Mac’s classic break-up song, “Go Your Own Way.”
Allow me to explain. Biotech venture capital has been going through a shakeout now for a couple years, which I’ve written about quite a bit. If you want to be charitable, there are maybe half as many venture firms investing in life sciences companies today as there were five to 10 years ago. There are maybe only a dozen firms left in the U.S. who can say with a straight face that they still are active investors in early-stage biotech startups. It may be harder now than it’s ever been to raise money for a new biotech idea.
Third Rock Ventures has spent the last six years betting big on early stage biotech investing when most other VC firms have been hunkering down or getting out of healthcare investing altogether. Now Third Rock has been rewarded with another $516 million to keep doing what it’s been doing.
The Boston and San Francisco-based firm, founded in 2007, said today it has raised its third fund, bringing its total assets under management to about $1.3 billion. The firm said this round was “oversubscribed” meaning that there wasn’t enough room to accommodate all the limited partners such as endowments and pensions who wanted a piece of the new fund.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
Join our sponsors, BioHealth Innovation, Inc. (BHI) and the Johns Hopkins University Center for Biotechnology Education, along with many others from our local biotech industry at another exciting BioBuzz event on March 20 from 4:30 – 7 p.m. in Gaithersburg. This month, we’re having our event a week early to accommodate BioBuzzers with kids in Montgomery County Public School system who will be on spring break the next week. We’re also holding the March BioBuzz event at a new location, Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!
Biopharmaceutical giant AstraZeneca announced today it plans to create a research and development center in Gaithersburg, adding 300 jobs at MedImmune’s current location.
MedImmune’s director of corporate public relations, Tracy Rossin, said no new buildings are planned at this point. Biotech company MedImmune, which is owned by AstraZeneca, currently houses AstraZeneca’s biologics programs, geared toward the creation of vaccines and medications.
Every week we give you a countdown of the top five to 10 companies or organizations from one of our Lists publishing in our Friday paper. This week I present to you the top five “Venture capital firms investing the most in Maryland companies,” ranked by total amount invested in Maryland companies in 2012. This information was provided to us by the folks at MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.
Rockville biotech Sequella inc. is looking to raise at least $20 million to advance its lead antibiotic candidate through clinical trials in drug-resistant tuberculosis and the stomach bacteria H. pylori.
If there ever was a time for the company to hit the gas pedal, it’s now. The resurgence of tuberculosis, especially in populous nations such as India and Russia, has brought what was thought of as a 19th century disease back into the spotlight. And the rise of multiple-drug-resistant strains of TB has made that fear very real in the mind of the U.S. consumer.
People looking to start a small business in Montgomery County can have some of their questions answered at a series of seminars focusing on small business in Germantown.
Three seminars will be held between March, April and May by Score DC, a chapter of the U.S. Service Corps and Retired Executives, and will have mentors on hand to discuss successful business practices.
As our April 5, 2013 receipt date approaches and you prepare your grant submission, please remember to work to register in all the required systems (DUNS, SAM, grants.gov, eRA Commons) in advance. These must all be complete before you can submit your grant application.
Company registration at SBA’s SBIR.gov is NOT required for submissions at this time. Solicitations issued after 1/28/2013 (not due dates for solicitations already on street prior to that date) will have instructions on how to register at SBA.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Request for Applications (RFAs):
RFA-OD-13-004: Lasker Clinical Research Scholars Program (Si2) This FOA solicits applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.
RFA-RM-12-022: NIH Director’s Biomedical Research Workforce Innovation Award: Broadening Experiences The purpose of this FOA is to seek, identify and support bold and innovative approaches to broaden graduate and postdoctoral training, such that training programs reflect the range of career options that trainees (regardless of funding source) ultimately may pursue and that are required for a robust biomedical, behavioral, social and clinical research enterprise. Collaborations with non-academic partners are encouraged to ensure that experts from a broad spectrum of research and research-related careers contribute to coursework, rotations, internships or other forms of exposure. This program will establish a new paradigm for graduate and postdoctoral training; awardee institutions will work together to define needs and share best practices.
RFA-RM-13-001: Planning Grants for the NIH Building Infrastructure Leading to Diversity (BUILD) Initiative (P20) The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions with expertise and innovative strategies for developing research and mentoring opportunities for undergraduate students from backgrounds underrepresented in biomedical research to submit applications for 6 month planning grants for the NIH Building Infrastructure Leading to Diversity (BUILD) initiative. The BUILD initiative aims to increase the diversity of the NIH-funded workforce by supporting collaborative programs that include novel approaches for enhancing undergraduate education, training, and mentorship, as well as infrastructure support and faculty development to facilitate those approaches.
RFA-RM-13-002: Planning Grants for the NIH National Research Mentoring Network (NRMN) (P20) The purpose of this Funding Opportunity Announcement (FOA) is to encourage organizations with experience in the mentorship of individuals underrepresented in the biomedical research workforce to submit planning grant applications for the NIH National Research Mentoring Network (NRMN). The NRMN will establish a nationwide consortium to provide networking and mentorship experiences for individuals from backgrounds underrepresented in biomedical research from the undergraduate to junior faculty level.
Program Announcement (PA):
PAR-13-137: Bioengineering Research Grants (BRG) (R01) The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach that can increase our understanding of and solve problems in biological, clinical or translational science.
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Known for its ancient castles and seaside mosques, the Turkish city of Trabzon is looking to raise its profile on a new front—biotechnology.
For inspiration on expanding the Trapzon region’s high-tech and environmental-based industry, a foreign delegation arrived in Baltimore on Tuesday to meet with the Maryland Department of Business & Economic Development.
At its annual meeting on March 8, the Maryland Business Incubation Association (MBIA) approved applications for membership for two new full incubator programs and one new associate program: The Harford Business Innovation Center, Betamore, and The Charles County Innovation Center (planning underway)—bringing current membership to 23 business incubators and innovation centers.
MBIA member organizations offer direct support to nearly 450 entrepreneurial ventures throughout the State from a wide variety of sectors. They foster entrepreneurship and contribute substantially to the Maryland economy through the creation of thousands of jobs and the generation of significant tax revenues.
In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient’s own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor.
The investigators say so-called mesenchymal stem cells (MSCs) have an unexplained ability to seek out damaged cells, such as those involved in cancer, and may provide clinicians a new tool for accessing difficult-to-reach parts of the brain where cancer cells can hide and proliferate anew. The researchers say harvesting MSCs from fat is less invasive and less expensive than getting them from bone marrow, a more commonly studied method.
Results of the Johns Hopkins proof-of-principle study are described online in the journal PLOS ONE.
Roughly three years after announcing that he was expanding his California bioscience incubator to San Antonio, InCube Labs founder Mir Imran may wish he had made the move even sooner.
InCube has found willing investors, as well as corporate and community support, in the nation’s seventh largest city. That has allowed the organization to adjust its expectations and strategies in a way that could prove to be hugely beneficial for the life sciences entity and for San Antonio long-term.
New Enterprise Associates, a venture capital firm that’s invested some $13 billion in up-and-coming companies, has launched a brand-new design mentorship program to fuel innovation in the design industry. Called NEA Studio, the 12-week program will challenge five designers at a time.
Why the focus on design? “When a consumer gets a product, it’s usually because of the design of it,” said Dayna Grayson, an NEA partner, to Fast Company. “I feel like, if you’re really going to design a product and make it inherent at a company, it has to start at a founder level. So if the designer wants to be the founder, why not?”
As part of the Wyle-led team, Lockheed Martin (NYSE: LMT) has been selected by NASA’s Johnson Space Center to provide biomedical, medical and health services in support of all human spaceflight programs. These services under the Human Health and Performance Contract (HHPC) monitor astronaut health and enable bioastronautics research that benefits life on Earth.
The potential contract value to Lockheed Martin is about $250 million over the expected 10-year life of the contract. Lockheed Martin is responsible for flight hardware development, facilitation of life sciences research conducted on the International Space Station (ISS), human factors engineering to optimize tools and experiments for astronauts in zero gravity, radiation analysis, space food development, flight/ground crew training, and life sciences data archival.
As advances in genomics, molecular analysis, and data processing have propelled disease research forward, scientists and drug developers still face a formidable challenge: recruiting patients for their studies.
Genetic Alliance, a nonprofit that advocates for people with rare genetic disorders, is launching a new site called Reg4All that aims to entice more patients into clinical trials and disease research by giving them unprecedented privacy controls and greater say in how their data is used for research.
After McKesson, Cerner, Allscripts, Greenway and athenahealth made news at HIMSS13 this past week with the launch of the CommonWell Health Alliance – putting aside their competitive instincts, for a moment, to pledge their common commitment to interoperability and data liquidity – Healthcare IT News spoke with McKesson CEO John Hammergren about the road ahead.
Joining Hammergren in the discussion were David McCallie, vice president, medical informatics at Cerner, and Arien Malec, vice president, data platform solutions for McKesson’s connectivity business, RelayHealth (and, in his former role at the Office of the National Coordinator for Health IT, the driving force behind the development of the Direct Project).
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
The Economic Alliance of Greater Baltimore (EAGB) and BioHealth Innovation (BHI) in collaboration with the Baltimore Business Journal are proud to announce the publication of the Central Maryland BioHealth Entrepreneur’s Resource and Financing Guide.
This Guide will be a compendium of resources to BioHealth innovators and entrepreneurs working to start and grow new companies in the region. A wealth of resources exists in Maryland to support emerging BioHealth companies, however, they are not always readily accessible or captured in one place. The Guide will compile information on financial resources, university facilities and programs, economic development programs, and existing federal laboratory facilities and programs and how to work with them.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
Join our sponsors, BioHealth Innovation, Inc. (BHI) and the Johns Hopkins University Center for Biotechnology Education, along with many others from our local biotech industry at another exciting BioBuzz event on March 20 from 4:30 – 7 p.m. in Gaithersburg. This month, we’re having our event a week early to accommodate BioBuzzers with kids in Montgomery County Public School system who will be on spring break the next week. We’re also holding the March BioBuzz event at a new location, Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!
Aronson’s Technology Industry Services Group is partnering with Rich Bendis and BioHealth Innovation (BHI) to help transform Central Maryland into a leading biohealth entrepreneurial and commercialization region.
“The central Maryland region is home to research organizations, government agencies, universities and companies with extensive biohealth experience and capabilities,” remarked Alan Langelli, Senior Manager in Aronson’s Technology Industry Services Group. He continued, “Aronson is very excited about the opportunity to partner with BHI and support its goal of helping Central Maryland become a leading biohealth entrepreneurial and commercialization region.”
BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking a Health Information Technology (IT) Entrepreneur-in-Residence.
POSITION DESCRIPTION – Health IT Entrepreneur-in-Residence The Health IT Entrepreneur-in-Residence (EIR) will lead in the evaluation of early-stage health IT technologies, advise BHI on opportunities for new ventures, and build a portfolio commercially relevant health IT opportunities. The Health IT EIR influences the BHI organization by managing and providing information, intelligence and insights that drive critical business decisions. The Health IT EIR will work with early stage companies to launch and validate those companies while providing recommendations and insights on the direction of potential technologies. The Health IT EIR has the potential to also serve in a co-management role in a health IT accelerator.
Personal Genome Diagnostics Inc. (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, today announced a number of developments that will support its expanding business. The company licensed exclusive rights to Digital Karyotyping (DK), an important genome-mapping technology developed by the company’s founders at Johns Hopkins University. PGDx also announced that it is expanding into new facilities and has made a number of key hires, including Genzyme Oncology executive Antony Newton as Chief Commercial Officer.
Johns Hopkins University generally does well on U.S. rankings of the top colleges.
But how does it stack up against institutions of higher learning from around the world? Not bad. It ranks No. 19 in the Times Higher Education World Reputation Rankings of the top 100 universities from around the globe. The University of Maryland, College Park also comes up on the list, at 95.
The University of Maryland, College Park has cracked the top 100 global reputation ranking by a publication based in the United Kingdom, The Washington Post reported.
Times Higher Education shows that UMd. is in a group ranked 91-100, in a class with Monash University in Australia, Lund in Sweden, Bristol in the U.K., the Free University of Berlin and Texas A&M. The rankings were based on surveys of academics around the world. Johns Hopkins, in Baltimore, ranked No. 19, the highest from the local region. Harvard University was ranked No. 1.
GlaxoSmithKline (GSK) has submitted its albiglutide once-weekly injection for type 2 diabetes to European regulators.
If approved the biologic treatment, which was submitted for US approval in January, will be marketed as Eperzan.
Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.
Montgomery County-based Novavax is a biopharmaceutical company creating nanoparticle vaccines targeting a wide array of infectious diseases. In this new video, CEO Stanley Erck speaks about the different processes Novavax scientists are working on, and the overall momentum of the company. Mr. Erck also highlights the company’s partnerships with Path, LG Life Sciences, GE Healthcare, and Cadila Pharmaceuticals. Novavax is excited by the promising new data from clinical trials with its RSV vaccine candidate and pandemic influenza vaccine candidate, and by the potential of its technology platform. From discovery to commercialization, Novavax is positioned to develop the vaccines for tomorrow.
A tax measure that would create a new, more lenient capital gains rate for tech investors and entrepreneurs cashing out their stock in the District is “going to be a focal point” for the Gray administration’s policy efforts this year, Mayor Vincent Gray told me in an interview Friday.
Gray, discussing his upcoming trip to the South by Southwest technology competition in Texas and his broader efforts to expand the District’s tech startup scene, acknowledged that resistance to the tax cut persists in the D.C. Council, which tabled the tax break last summer:
“I don’t get the sense that they’re any further along,” he said.
Nevro Corp., a medical device company focused on improving pain relief in patients suffering from debilitating chronic pain, today announced it has completed a $48 million Series C financing round. The round was led by new investor Novo Ventures, joined by New Enterprise Associates (NEA) and Covidien Ventures. Existing investors participating in this financing round included Accuitive Medical Ventures (AMV), Bay City Capital, Johnson & Johnson Development Corporation (JJDC), Mayo Clinic, MPM Capital, and Three Arch Partners.
“We are excited to welcome premier investors Novo Ventures, NEA, and Covidien Ventures who share Nevro’s vision to be a leader in neuromodulation through continuous innovation”
Personalized medicine — the ability to tailor therapies to patients’ individual genetic characteristics — has long been the holy grail of the life sciences industry. The effort has produced a string of recent successes, including a host of drugs targeted to people with specific genetic profiles, the European approval of the world’s first gene therapy treatment, and a much-heralded leukemia treatment pioneered at Children’s Hospital of Philadelphia (CHOP) that uses tweaked versions of patients’ own cells to eliminate their cancer. While these advances are certainly exciting for patients, they raise a host of ethical, legal and financial challenges that people working in the field will need to address before personalized medicine can become a thriving business.
The challenges are so great, contends Wharton health care management professor Ezekiel J. Emanuel, that claims of a renaissance in medicine brought on by individualized approaches often seem hyperbolic. “Before we buy into this, we need to remember that almost every evaluation of what drives health care costs up points to new technologies,” says Emanuel, who is also a professor of medical ethics and health policy at Penn’s Perelman School of Medicine. “We need to be skeptical. We need to see the data before people buy into the idea that personalized medicine is going to produce cost savings and be so much better for the system.”
She sent her first tweet just after noon, and already Kathleen Sebelius (@Sebelius) has 2,000-plus followers.
The secretary of U.S. Health and Human Services is the latest federal health official to join Twitter and follows in the footsteps of colleagues Dr. Tom Frieden (@DrFriedenCDC), the director of the U.S. Centers for Disease Control and Prevention, and Dr. Francis Collins (@NIHDirector), director of the National Institutes of Health.
Big news was made at HIMSS13 on Monday when, in an unprecedented collaboration, some health IT heavy-hitters joined forces in an effort to push the needle on interoperability.
In announcing the launch of the CommonWell Health Alliance, executives from Cerner, McKesson, Allscripts, athenahealth, Greenway and RelayHealth touted what they say is a first-of-its-kind organization: a collaboration of rival vendors, uniting to enable care integration and data liquidity.
A little more than a month ago, Naomi Fried, chief innovation officer at Boston Children’s Hospital, tweeted: that most healthcare mobile apps are built for consumers and focus on health and wellness, while only 20 percent are clinical apps. She wrote: “We need more #hospital apps.” Naturally, this caught our attention.
“There’s a huge opportunity for mobile apps in the hospital environment,” Fried told MobiHealthNews in an interview ahead of the annual Healthcare Information and Management Systems Society (HIMSS) conference. Fried will be receiving a HIT Men & Women Award at HIMSS in New Orleans this week for being an up-and-coming innovator.
In 2009, President Barack Obama selected the Republic of Turkey as a pivotal port of call in his first trip abroad as the new President of the United States. That symbolic visit led to the launch of an initiative to boost trade and investment ties between the two strategic allies under what was called a “model partnership,” culminating in a $ 17 billion mutual trade volume. Following in the footsteps of the President, US Senator John Kerry will also visit Turkey in his first international tour as the new American Secretary of State. These visits further underline the significance of American-Turkish relations for this administration. As the 16th strongest economy in the world, Turkey is not only an important geopolitical ally, but also an increasingly valuable commercial partner.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
I had the privilege to meet with and speak to the local Healthcare meet-up recently (thanks to Pete Kanee at www.healthcare.mn) and as part of my discussion, I shared a list of things that I’d encourage the local (healthcare) startups to continue to keep in mind as they grow their companies.
In a move sure to inflame the libertarian blogosphere, a presidential ethics commission recommended today that researchers study the effects of anthrax vaccine on children.
Montgomery County has a plan to market itself as a business and tourist destination to a particularly captive audience — one traveling at 30,000 feet.
Please join us to learn more about the uniqueness of Aeras: the product development partnership model, funding, center of excellence and CMO capabilities. Aeras, a not-for-profit, product development organization focused on developing safe, effective vaccines to prevent TB and ensuring they will be available and affordable for the populations that most need them.
Join us on March 20 at Growlers for another BioBuzz Happy Hour
BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable health IT products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking a Health Information Technology (IT) Entrepreneur-in-Residence.
She sent her first tweet just after noon, and already Kathleen Sebelius (@Sebelius) has 2,000-plus followers.
ittle more than a month ago, Naomi Fried, chief innovation officer at Boston Children’s Hospital, tweeted: that most healthcare mobile apps are built for consumers and focus on health and wellness, while only 20 percent are clinical apps. She wrote: “We need more #hospital apps.” Naturally, this caught our attention.
In 2009, President Barack Obama selected the Republic of Turkey as a pivotal port of call in his first trip abroad as the new President of the United States. That symbolic visit led to the launch of an initiative to boost trade and investment ties between the two strategic allies under what was called a “model partnership,” culminating in a $ 17 billion mutual trade volume. Following in the footsteps of the President, US Senator John Kerry will also visit Turkey in his first international tour as the new American Secretary of State. These visits further underline the significance of American-Turkish relations for this administration. As the 16th strongest economy in the world, Turkey is not only an important geopolitical ally, but also an increasingly valuable commercial partner.